Healthcare Sales & Marketing Network News: fostamatinib

Searching News Database: fostamatinib

HSMN NewsFeed - 15 Dec 2017
Rigel Announces Departure of Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Aug 2017
Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Jun 2017
FDA Accepts Rigel's New Drug Application for TAVALISSE(TM) (fostamatinib disodium) for the Treatment of Chronic ITP
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Apr 2017
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2017
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
Biopharmaceuticals

HSMN NewsFeed - 7 Oct 2016
Rigel Expands Leadership Team in Research and Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Oct 2013
Rigel Provides Pipeline Update
Biopharmaceuticals

HSMN NewsFeed - 19 Jun 2012
AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 16 Feb 2010
AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA)
Biopharmaceuticals Licensing

Return to NewsFeed

RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.

RepFinder 2 - available on the Apple App Store for iPhone and iPad.